Tango faces a fresh PRMT5 competitor
New clinical trial listings reveal first-in-human studies for Astra’s AZD3470, a new Car-T therapy from Caribou, a B7-H4 challenger and others.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
ESMO 2023 – sabestomig has it all to do in TIM-3
Astra manages to avoid the toxicities that scuppered Lilly’s PD-1 x TIM-3 contender, but still needs to dial up sabestomig’s efficacy.
ESMO 2023 – GSK sets up Pfizer battle in B7-H4
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
First phase 1 starters challenge Pluvicto and Revolution
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Interest builds in a new synthetic lethality story
Ideaya and GSK join Novartis and Roche in the Werner helicase inhibitor race.
